European regulators approve AstraZeneca diabetes medicine


AstraZeneca announced that the European Commission (EC) approved Qtrilmet(metformin hydrochloride, saxagliptin, and dapagliflozin) modified-release tablets to improve glycaemic control in some adults with type-2 diabetes.

Across the trials, the combination of Forxiga, Onglyza,and metformin fared outperformed other combinations.

The EC has approved Qtrilmet to improve glycaemic control for ome patients.

Qtrilmet was approved in the US in May under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes.

Qtrilmetis a once-daily oral medicine comprised of the selective sodium‑glucose co-transporter 2 (SGLT2) inhibitorForxiga, the dipeptidyl peptidase‑4 (DPP‑4) inhibitorOnglyzaand metformin hydrochloride extended-release.

AstraZeneca employs 1,500 in northern Delaware.

Facebook Comments
Previous articleGood news at the pump as Thanksgiving holiday approaches
Posts labeled Special to Delaware Business Now are typically submitted items that are updated and sometimes rewritten in news style. Background information is sometimes added.